Molecular Insights into Fully Human and Humanized Monoclonal Antibodies: What are the Differences and Should Dermatologists Care?
In recent years, a large number of therapeutic monoclonal antibodies have come to market to treat a variety of conditions including patients with immune-mediated chronic inflammation. Distinguishing the relative clinical efficacy and safety profiles of one monoclonal antibody relative to another can be difficult and complex due to different clinical designs and paucity of head-to-head comparator studies. One distinguishing feature in interpreting clinical trial data by dermatologists may begin by determining whether a monoclonal antibody is fully human or humanized, which can be discerned by the generic name of the drug. Herein, this commentary highlights the distinctions and similarities of fully human and humanized monoclonal antibodies in their nomenclature, engineering, and clinical profiles. While there are a number of differences between these types of monoclonal antibodies, current evidence indicates that this designation does not impart any measurable impact on overall clinical efficacy and safety profiles of a given drug. Based on molecular insights provided in this commentary, it is clear that each monoclonal antibody, irrespective of being fully human or humanized, should be individually assessed for its clinical impact regarding safety and efficacy. Going beyond the type of generic name ascribed to a monoclonal antibody will be an ever-increasing theme for dermatologists as more therapeutic monoclonal antibodies emerge to potentially treat a wider scope of diseases with cutaneous manifestations.
Eli Lilly and Company, Indianapolis, Indiana.
Lotus
L
Mallbris
Eli Lilly and Company, Indianapolis, Indiana.
Julian
J
Davies
Eli Lilly and Company, Indianapolis, Indiana.
Andrew
A
Glasebrook
Eli Lilly and Company, Indianapolis, Indiana.
Ying
Y
Tang
Eli Lilly and Company, Indianapolis, Indiana.
Wolfgang
W
Glaesner
Eli Lilly and Company, Indianapolis, Indiana.
Brian J
BJ
Nickoloff
MAbs. 2010 May-Jun;2(3):256-65
20400861
Annu Rev Biochem. 2007;76:1-22
17328676
J Invest Dermatol. 2015 Jan;135(1):31-8
25120005
Br J Dermatol. 2014 Feb;170(2):261-73
24117166
MAbs. 2016;8(1):1-9
26716992
Methods. 2005 May;36(1):3-10
15848070
J Inflamm Res. 2016 Apr 19;9:39-50
27143947
Curr Opin Immunol. 2016 Jun;40:62-9
27003675
MAbs. 2011 May-Jun;3(3):243-52
21406966
Curr Opin Struct Biol. 2016 Aug;39:79-88
27322891